REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $31.88.

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group lowered shares of REGENXBIO from a "buy" rating to a "neutral" rating and dropped their price target for the company from $38.00 to $14.00 in a research report on Tuesday, February 11th. Raymond James assumed coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price on the stock. Chardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Finally, Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th.

Check Out Our Latest Analysis on REGENXBIO

Institutional Trading of REGENXBIO

Institutional investors have recently modified their holdings of the company. FMR LLC boosted its stake in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,656 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after acquiring an additional 17,533 shares during the period. Stifel Financial Corp lifted its holdings in shares of REGENXBIO by 13.3% during the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock worth $1,566,000 after acquiring an additional 17,563 shares during the period. Barclays PLC boosted its position in shares of REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock valued at $1,217,000 after acquiring an additional 67,948 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in REGENXBIO by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company's stock valued at $11,422,000 after acquiring an additional 44,037 shares during the period. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Stock Up 3.5 %

NASDAQ RGNX opened at $6.55 on Wednesday. The company has a 50 day moving average price of $6.92 and a two-hundred day moving average price of $8.23. REGENXBIO has a 12-month low of $5.04 and a 12-month high of $18.24. The stock has a market capitalization of $328.27 million, a PE ratio of -1.30 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. As a group, equities analysts anticipate that REGENXBIO will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Read More

• Five stocks we like better than REGENXBIO
• How to Invest in Biotech Stocks
• Beware of BigBear.ai: Insiders Are Selling—Should You?
• How to Plot Fibonacci Price Inflection Levels
• CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
• Stock Market Sectors: What Are They and How Many Are There?
• Congress! Who Traded What During the Tariff-Induced Meltdown

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in REGENXBIO Right Now?

Before you consider REGENXBIO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.

While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here